NYSE:ALR - Alere Stock Price, Price Target & More

Notice: This company has been marked as potentially delisted and may not be actively trading.
Sign in or create an account to add this stock to your watchlist.
$3.52 -0.16 (-4.35 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$3.68
Today's Range$3.40 - $3.55
52-Week Range$34.41 - $51.00
Volume27,060 shs
Average Volume1.53 million shs
Market Capitalization$4.47 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.21
Alere logoAlere Inc. is a provider of health information through diagnostic tests. The Company's segments include professional diagnostics, consumer diagnostics, and corporate and other. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus. The consumer diagnostics segment consists primarily of manufacturing operations related to its role as the exclusive manufacturer of products for SPD Swiss Precision Diagnostics (SPD), its joint venture with The Procter & Gamble Company (P&G). The Company's professional diagnostic solutions allow patients and their healthcare providers to work together to manage patients' conditions over the continuum of care, from the hospital to home. The Company offers lines of drugs-of-abuse tests, reagent systems and laboratory testing options.

Receive ALR News and Ratings via Email

Sign-up to receive the latest news and ratings for ALR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry N/A
Sub-IndustryHealth Care Supplies
SectorN/A
SymbolNYSE:ALR
CUSIP01449J10
Phone+1-781-6473900

Debt

Debt-to-Equity Ratio2.43
Current Ratio2.04
Quick Ratio1.54

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-16.86%
Return on Equity-33.39%
Return on Assets-6.72%

Miscellaneous

Employees9,700
Outstanding Shares87,580,000
Market Cap$4,470.00

Alere (NYSE:ALR) Frequently Asked Questions

What is Alere's stock symbol?

Alere trades on the New York Stock Exchange (NYSE) under the ticker symbol "ALR."

How were Alere's earnings last quarter?

Alere Inc (NYSE:ALR) issued its quarterly earnings data on Friday, November, 4th. The medical research company reported $0.19 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.54 by $0.35. The medical research company earned $582 million during the quarter, compared to the consensus estimate of $605.50 million. Alere had a negative net margin of 16.86% and a negative return on equity of 33.39%. Alere's revenue for the quarter was down 3.6% on a year-over-year basis. During the same period in the previous year, the company earned ($0.10) EPS. View Alere's Earnings History.

What price target have analysts set for ALR?

1 brokerages have issued 12-month price targets for Alere's stock. Their predictions range from $51.00 to $51.00. On average, they expect Alere's stock price to reach $51.00 in the next twelve months. This suggests a possible upside of 1,348.9% from the stock's current price. View Analyst Ratings for Alere.

What is the consensus analysts' recommendation for Alere?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alere in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold."

Who are Alere's key executives?

Alere's management team includes the folowing people:
  • Gregg J. Powers, Independent Chairman of the Board
  • Namal Nawana, President, Chief Executive Officer, Director
  • James F. Hinrichs, Chief Financial Officer, Executive Vice President
  • Daniella Cramp, Global President - Cardiometabolic Business Unit
  • Sanjay Malkani, Global President - Toxicology
  • Avi Pelossof, Global President - Infectious Disease Business Unit
  • Ellen Chiniara J.D., Senior Vice President, General Counsel, Chief Ethics and Compliance Officer, Secretary
  • Robert Hargadon, Senior Vice President - Global Human Resources
  • John Bridgen Ph.D., Senior Vice President - Business Development
  • Mark Gladwell, Senior Vice President - Global Operations

Has Alere been receiving favorable news coverage?

News stories about ALR stock have trended somewhat positive this week, Accern reports. The research group rates the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Alere earned a news sentiment score of 0.02 on Accern's scale. They also assigned media headlines about the medical research company an impact score of 45.38 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

What is Alere's stock price today?

One share of ALR stock can currently be purchased for approximately $3.52.

How big of a company is Alere?

Alere has a market capitalization of $4.47 billion. Alere employs 9,700 workers across the globe.

How can I contact Alere?

Alere's mailing address is 51 Sawyer Rd Ste 200, WALTHAM, MA 02453-3448, United States. The medical research company can be reached via phone at +1-781-6473900.


MarketBeat Community Rating for Alere (NYSE ALR)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  318 (Vote Outperform)
Underperform Votes:  335 (Vote Underperform)
Total Votes:  653
MarketBeat's community ratings are surveys of what our community members think about Alere and other stocks. Vote "Outperform" if you believe ALR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.